(Total Views: 978)
Posted On: 11/01/2019 4:47:55 PM
Post# of 416
NetworkNewsBreaks – Endonovo Therapeutics Inc. (ENDV) Announces Reverse Stock Split
Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, on Thursday announced its filing of a preliminary information statement with respect to a proposed reverse stock split of its common stock at a ratio of between 1 for 100 and 1-for-1,000. According to the update, the proposed reverse stock split effectiveness is contingent upon final SEC clearance of the Information Statement, mailing of the statement and a twenty-day waiting period, Endonovo’s sole director’s decision as to the final ratio of the reverse stock split, filing of a certificate of amendment to the company’s certificate of incorporation, and review of the proposal by FINRA. “This reverse stock split is an important step in our future and our goal for growing the company and creating long-term shareholder value and attracting a broader, more diverse shareholder base, especially in light of the SofPulse(R) sales and our national rollout,” Endonovo Therapeutics CEO Alan Collier said in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, on Thursday announced its filing of a preliminary information statement with respect to a proposed reverse stock split of its common stock at a ratio of between 1 for 100 and 1-for-1,000. According to the update, the proposed reverse stock split effectiveness is contingent upon final SEC clearance of the Information Statement, mailing of the statement and a twenty-day waiting period, Endonovo’s sole director’s decision as to the final ratio of the reverse stock split, filing of a certificate of amendment to the company’s certificate of incorporation, and review of the proposal by FINRA. “This reverse stock split is an important step in our future and our goal for growing the company and creating long-term shareholder value and attracting a broader, more diverse shareholder base, especially in light of the SofPulse(R) sales and our national rollout,” Endonovo Therapeutics CEO Alan Collier said in the news release.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)
